Probing depth changes following 2 years of periodontal maintenance therapy including adjunctive controlled release of chlorhexidine.
BACKGROUND
Multicenter clinical trials have established that the adjunctive use of the subgingival controlled release of chlorhexidine, (CHX chip), significantly reduces probing depth (PD), improves clinical attachment levels, and reduces bleeding on probing compared to scaling and root planing (SRP) alone for periods of up to 9 months. The present report is based on a phase IV clinical trial to examine the adjunctive use of the CHX chip for routine periodontal maintenance therapy (RPMT) over 2 years.


METHODS
Eight hundred thirty-five (835) patients were recruited into the study. At baseline a CHX chip was placed in pocket sites with PD > or = 5 mm. The patients were scheduled to receive RPMT at 3-month intervals with repeated CHX chip placement at sites where the PD remained > or = 5 mm. Patients who did not attend the 24-month recall visit or who failed to attend 2 consecutive time frame examinations were excluded from the analyses.


RESULTS
The 595 patients included showed a continuous decrease in PD over 2 years of 0.95 mm. After 2 years, 23.2% of patients had at least 2 pockets showing a reduction in PD of 2 mm or more and 58.9% of the sites had been reduced to a PD of < 5 mm. Only 2.9% (n = 57) of the sites showed an increase in PD of > or = 2 mm. Adverse events were mild to moderate in nature and resolved spontaneously without medication.


CONCLUSIONS
The results of this Phase IV or follow-up trial indicate that the adjunctive use of the CHX chip is a clinically safe and effective treatment option for long-term management of chronic periodontitis.
Soskolne
W Aubrey
WA
Department of Periodontics, Hebrew University-Hadassah Faculty of Dental Medicine, Jerusalem, Israel. sosko@cc.huji.ac.il
Proskin
Howard M
HM
Stabholz
Ayala
A
D000328:Adult; D000368:Aged; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002710:Chlorhexidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D002908:Chronic Disease; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012534:Dental Scaling; D005157:Facial Pain / Q000139:chemically induced; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010512:Periodontal Index; D010514:Periodontal Pocket / Q000473:pathology; D010518:Periodontitis / Q000517:prevention & control*
D000891:Anti-Infective Agents, Local; D003692:Delayed-Action Preparations; C010882:chlorhexidine gluconate; D002710:Chlorhexidine